Journal of Renal Cancer

Home / Browse Journals & Books / Journal of Renal Cancer / Archive / Volume 1, Issue 1

Table of Content: Volume 1, Issue 1

Select All | |

Commentary Pages 9-11

The Mainstay of Treatment will be Changed: Cytoreductive Nephrectomy Would Not be Required in Intermediate and Poor Risk Patients with Metastatic Renal Cell Carcinoma Cancer

Authors: Ilya Tsimafeyeu

Abstract: To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the first-line treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.

| | |

Case Report Pages 7-8

Meningeal Carcinomatosis in a Patient with an Upper Urinary Tract Urothelial Cell Carcinoma

Authors: Rosa Maria Martin Diaz, Fernando Moreno Anton, Montserrat Lopez Carreira, Ignacio Juez Martel and Ana Isabel Franco Moreno

Abstract: Meningeal carcinomatosis (MC) is an infrequent of the solid tumors, normally in advanced stages of the disease. It has a very poor prognosis, with a median survival less than 6 month. To our knowledge, meningeal carcinomatosis from upper urinary tract urothelial cell carcinoma (UUT-UCC) has not been reported.

| | |

Research Article Pages 1-6

Efficacy and Safety of Sunitinib in Elderly Patients with Advanced Renal Cell Carcinoma at a University Hospital in Japan: Before Immuno-Oncology Therapy Era

Authors: Tatsuya Takayama, Akira Fujisaki, Satoshi Ando, Shinsuke Kurokawa and Tatsuo Morita

Abstract: Japan is a front-line country in the coming super-aging society. As with all cancers in the elderly, the frequency of renal cell carcinoma (RCC) is also increasing in Japan. While clinical encounters with elderly patients with advanced RCC increase, these patients are only infrequently entered into clinical trials [3], and efficacy and safety data in this age range are scarce.

| | |

Publish with Scholars.Direct

Track your Manuscript Status

(Please write to editorialoffice@scholars.direct in case of any technical error)